-
Mashup Score: 56A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma - 6 day(s) ago
Key Points. Axi-cel and liso-cel had similar outcomes, though when accounting for differences in risk factors, axi-cel was associated with superior PFS.We
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 54A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma - 7 day(s) ago
Key Points. Axi-cel and liso-cel had similar outcomes, though when accounting for differences in risk factors, axi-cel was associated with superior PFS.We
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Super interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm https://t.co/Q60R0zlaS9
-
-
Mashup Score: 1Mehdi Hamadani (@medihumdani.bsky.social) - 12 day(s) ago
BMT & Cellular Therapy | Secretary @ASTCT | Co-Chair @ASTCT CoPG | #bmtsm #CARTcell #lymsm | Personal views | Physician not Provider | 🇵🇰 🏏 🇺🇸 🏈
Source: bsky.appCategories: General Medicine News, Hem/OncsTweet-
Don't believe in Echo chambers, but will also be posting at @bluesky https://t.co/wseaULBNmR
-
-
Mashup Score: 54Real‐world treatment of large B‐cell lymphoma with chimeric antigen receptor T‐cell therapy after loncastuximab tesirine - 1 month(s) agoSource: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
With increasing pola using in frontline, is CD19 bridge to CD19 CAR possible? We think so, with CD19 directed ADC loncastuximab in @CIBMTR database #lymsm https://t.co/gwIrGA3133
-
-
Mashup Score: 105
Colony-stimulating factor 1 receptor (CSF1R)–dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic hematopo…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
AGAVE 201 out in @NEJM. Remarkable efficacy of axatilimab (blocking CSF1R) in chronic #GvHD. I have some phenomenal response on trial. -Look for puffy eyes - Artifact elevation of AST/ALT/amylase/lipase due to inhibition of kupffer cells @Chhabra_mayo https://t.co/Cm3VHV5Rb4
-
-
Mashup Score: 86Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy - 3 month(s) ago
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Utah Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI Department of Medicine, Weill
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet-
Our analysis of CAR-T in #PCNSL, CIBMTR N=24; median age 57; 88% active disease; median piror Rx4; ORR 61%; 2yr OS/PFS 50%/28%; NRM 0; CRS 67%; no G3-4. ICANS 33%; 2 with grade or higher. #lymsm #CART @CatherineLeeMD @mshadman @hemant_murthy et al. https://t.co/RbM02ICClE https://t.co/5t1DS9wuZZ
-
-
Mashup Score: 81Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy - 3 month(s) ago
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Utah Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI Department of Medicine, Weill
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet-
Our analysis of CAR-T in #PCNSL, CIBMTR N=24; median age 57; 88% active disease; median piror Rx4; ORR 61%; 2yr OS/PFS 50%/28%; NRM 0; CRS 67%; no G3-4. ICANS 33%; 2 with grade or higher. #lymsm #CART @CatherineLeeMD @mshadman @hemant_murthy et al. https://t.co/RbM02ICClE https://t.co/5t1DS9wuZZ
-
-
Mashup Score: 68
Key Points. Among 58 patients who received CD19-directed CART cells for T cell/Histiocyte Rich Large B-cell Lymphoma, the 2-year PFS was 29%.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma #lymsm @priyankapophali @joshuaafein @mshadman @RShouval @NausheenAhmedMD et al. N=58 2-year OS 42%, PFS 29% (better than initial reports) https://t.co/BcoSYZgPy2
-
-
Mashup Score: 68
Key Points. Among 58 patients who received CD19-directed CART cells for T cell/Histiocyte Rich Large B-cell Lymphoma, the 2-year PFS was 29%.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma #lymsm @priyankapophali @joshuaafein @mshadman @RShouval @NausheenAhmedMD et al. N=58 2-year OS 42%, PFS 29% (better than initial reports) https://t.co/BcoSYZgPy2
-
-
Mashup Score: 8Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission - 5 month(s) ago
Blood Cancer Journal – Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
3/x our analysis below @mshadman provides some guidance for such situations. https://t.co/w8qCCsom4c [by no means a substitute for randomized data but this is what we have]
-
Super interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm https://t.co/Q60R0zlaS9